Ente Ospedaliero Ospedali Galliera Di Genova

At Ente Ospedaliero Ospedali Galliera Di Genova, a major focus is on hemic and lymphatic diseases, especially inherited anemias and related blood conditions. The studies explore beta-thalassemia, alpha-thalassemia, sickle cell disease, and myelodysplastic syndrome, with the goal of improving anemia control, reducing transfusion burden, and assessing long-term safety of new treatment options.

• Testing new therapies for transfusion-dependent thalassemia and non-transfusion-dependent thalassemia
• Evaluating treatments for sickle cell disease and painful crisis prevention
• Monitoring safety in chronic blood disorder care, including iron overload and marrow-related conditions

This research reflects the site’s strong specialization in congenital blood disorders and efforts to improve everyday management for patients with chronic hematologic disease.

The site is also active in neoplasms, with trials spanning breast cancer, ovarian cancer, colorectal cancer, and prostate cancer. Research here aims to refine treatment effectiveness, compare therapeutic strategies, and study prevention approaches for people at increased cancer risk.

• Comparing treatment approaches for early breast cancer and recurrent ovarian cancer
• Studying colorectal cancer treatment intensification after surgery
• Exploring prevention and risk reduction in women with elevated breast cancer risk

These studies combine treatment evaluation with prevention research, showing a broad oncology portfolio at the Genoa hospital site.

Another important area involves diagnosis and advanced imaging for cancer detection. Trials are assessing PET-based tools for prostate cancer and prostatic recurrence, with the aim of improving the identification of disease spread and helping guide more precise treatment decisions.

• Evaluating imaging methods for detecting pelvic lymph node metastasis
• Assessing diagnostic accuracy in local prostate cancer recurrence
• Comparing molecular imaging approaches to improve cancer staging

This line of research supports earlier and more accurate diagnosis, especially in patients where standard methods are less informative.

The trial portfolio also includes respiratory tract diseases and rare conditions such as nontuberculous mycobacterial lung infection and erythropoietic protoporphyria. These studies focus on symptom relief, disease control, and long-term tolerability of treatments in conditions that can be difficult to manage.

• Improving respiratory symptoms in chronic lung infection
• Reducing light-related pain in protoporphyria
• Assessing the safety of long-term treatment in rare disease care

The research highlights the site’s interest in both rare disorders and quality-of-life outcomes, not only disease endpoints.

Trials in cardiovascular diseases at this site include work on preventing recurrent venous thromboembolism. These studies are designed to understand whether new approaches can lower the risk of repeat clotting events while maintaining acceptable safety.

• Preventing recurrence after deep vein thrombosis and pulmonary embolism
• Balancing effectiveness with bleeding risk in long-term clot prevention
• Supporting better secondary prevention strategies in older patients

This area adds an important preventive medicine dimension to the site’s broader clinical research program.